Growth factor receptors with tyrosine kinase activities such as EGFR, HER-2/neu, and c-Kit have recently emerged as promising targets for novel therapeutic agents, especially in some poorly chemosensitive neoplasms (Krause and Van Etten, 2005). This evidence concerns the gene ERBB2 and neoplasm.